Ewing sarcoma is a rare, aggressive cancer that grows in bones or the soft tissue around them. It primarily affects children, teenagers, and young adults, with a median age at diagnosis of 11 years. When the disease is caught before it spreads, the five-year survival rate is 75% to 85%. Once it has metastasized, that number drops to around 27% to 30%.
Where Ewing Sarcoma Develops
The most common sites are the long bones of the legs (about 33% of cases), the pelvis (24%), and the chest wall or ribs (18%). Unlike many bone cancers that form near the ends of bones, Ewing sarcoma often starts in the middle of the bone shaft and grows outward through the hard outer layer into surrounding soft tissue. It can also arise in soft tissue without involving bone at all, though this is less common.
When the cancer spreads, the lungs, other bones, and bone marrow are the most frequent destinations.
What Drives the Cancer
Nearly all Ewing sarcomas share one defining feature: a genetic accident in which two chromosomes swap pieces of DNA, fusing parts of two genes that don’t normally belong together. In roughly 85% of tumors, this creates a hybrid protein called EWSR1-FLI1. This protein acts like a rogue switch, hijacking the cell’s gene-reading machinery to turn on growth programs that should stay off and shut down ones that keep cells in check.
The fusion protein is essential for the tumor’s survival, yet the cells can’t tolerate too much of it either. Overproduction causes the cancer cells to stop dividing and die. This narrow window of tolerance is something researchers are actively trying to exploit. The protein also appears capable of transforming normal stem cells found in bone and connective tissue into cancerous ones, which helps explain why Ewing sarcoma tends to affect young people whose bones are still actively growing.
Symptoms to Recognize
Pain at the tumor site is the most common early symptom, and it often gets worse at night or during activity. Because Ewing sarcoma typically affects active children and teens, pain is frequently chalked up to a sports injury or growing pains, which can delay diagnosis. Swelling or a firm lump near the bone may develop over weeks to months. Some children also experience fever, fatigue, and unintentional weight loss, symptoms that can mimic an infection.
When the tumor is in the pelvis, symptoms tend to appear later because there’s more room for the mass to grow before it causes noticeable problems. Pelvic tumors may cause vague hip or back pain, limping, or difficulty with bladder or bowel function. Tumors in the ribs or chest wall can cause chest pain or difficulty breathing.
How It’s Diagnosed
Diagnosis requires imaging, a biopsy, and often genetic testing working together. On X-rays, the bone typically shows areas of destruction where the tumor has eaten through normal bone. Sometimes the outer layer of bone reacts by laying down new layers in a pattern sometimes described as “onion peel” layering, though this finding is neither always present in Ewing sarcoma nor exclusive to it. Other patterns, including a honeycomb appearance or irregular bone thickening, are also common.
MRI provides a clearer picture of how far the tumor extends into surrounding soft tissue, while a CT scan of the lungs checks for spread. A bone scan or PET scan evaluates whether other bones are involved. The definitive step is a biopsy, where a small sample of tumor tissue is examined under a microscope and tested for the characteristic gene fusion. Finding the EWSR1-FLI1 fusion (or one of the rarer related fusions) essentially confirms the diagnosis.
Treatment Approach
Treatment combines chemotherapy with local control of the tumor through surgery, radiation, or both. Chemotherapy comes first, typically starting with several cycles before any operation. This serves two purposes: it shrinks the primary tumor, making surgery easier or even possible, and it attacks any microscopic cancer cells that may have already spread elsewhere in the body.
The standard regimen alternates between two drug combinations. One includes vincristine, doxorubicin, and cyclophosphamide. The other pairs ifosfamide with etoposide. These cycles alternate over the course of many months. Around week 12, doctors evaluate the tumor to decide whether surgery, radiation, or a combination offers the best chance of removing or destroying it while preserving as much function as possible. Surgery is generally preferred when the tumor can be removed without causing major disability. Radiation is used when surgery would be too damaging or when the tumor’s location makes complete removal difficult. Chemotherapy continues after local treatment is completed.
Factors That Affect Outlook
The single most important factor is whether the cancer has spread at the time of diagnosis. Localized disease carries a five-year overall survival of around 85%, while metastatic disease drops to roughly 27%. Where the tumor is located also matters. Tumors in the arms or legs tend to have better outcomes than those in the pelvis, partly because extremity tumors are easier to remove surgically and tend to be found earlier. Pelvic tumors were independently associated with lower survival in long-term studies.
How well the tumor responds to initial chemotherapy is another strong predictor. When surgeons examine the removed tumor and find that chemotherapy killed most of the cancer cells, the outlook is significantly better than when a large proportion of living tumor cells remain.
Life After Treatment
Surviving Ewing sarcoma is only part of the story. In long-term follow-up studies with a median of 13.5 years after diagnosis, 77% of survivors who reached the five-year mark were living with chronic health effects from their treatment. The most common were musculoskeletal problems, affecting half of all long-term survivors. These include limb-length differences after surgery, joint stiffness, reduced range of motion, or bone weakness in areas that received radiation.
Cardiac toxicity affected 28% of survivors, a consequence of doxorubicin, one of the core chemotherapy drugs. This can show up years or even decades later as weakened heart muscle or heart failure, which is why survivors need ongoing heart monitoring. There is also a measurable risk of developing a second, unrelated cancer later in life. The cumulative risk reached about 5% at 10 years after diagnosis, driven largely by radiation exposure and certain chemotherapy agents. These long-term risks make consistent follow-up care essential for anyone who has been treated for Ewing sarcoma, even years after the original cancer is gone.